OBJECTIVES: Current vaccination schedule in Slovenia before 8 years of age includes 4 doses of a pentavalent (combined diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b; DTPa-IPV/Hib) vaccine (administered before 24 months of age) and 3 doses of a hepatitis B (hepB) vaccine (last dose administered between 5 and 6 years of age). The pentavalent vaccine could be replaced with a hexavalent (DTPa-IPV-hepB/Hib) vaccine administered before 18 months of age potentially combined with the co-administration of Measles-Mumps-Rubella (MMR) and Tdap vaccines at 7 years (currently administered at 5-6 and 8 years respectively). This analysis assesses the potential annual budget impact of alternative child vaccination schedules in Slovenia. METHODS:  The annual budget associated with the current and alternative vaccination schedules was estimated from the vaccine costs, the administration costs (1 per visit), the vaccination coverage (95% except hepB vaccine alone: 89%) and the birth cohort (21,000 newborns). A public health perspective was used. Unit costs (vaccine and administration) were estimated from official tariffs and coverage from currently observed coverage. The following schedules were investigated: (1) current; (2) hexavalent 3+1 doses; (3) hexavalent 3+1 with 4^th dose co-administered with MMR and co-administration of Tdap/MMR at 7 years old; (4) hexavalent 2+1 and (5) hexavalent 2+1 with same co-administration as in schedule (3). RESULTS: The annual budget associated with the current vaccination schedule was estimated at 4,344,124€. The alternative schedules lead for (2) and (3) to a budget increase of respectively €728,866 and €517,692. Schedules (4) and (5) lead to a respective annual budget saving of €259,776 and €470,950 as compared to the budget associated with the current schedule. CONCLUSIONS: Applying an alternative 2+1 hexavalent vaccination schedule could reduce the overall vaccination budget in Slovenia by up to 0.47 million euros whilst potentially allowing to improve hepB immunization coverage.